The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy

Authors:
  • BABlanche P. Alter
    Blanche P. Alter
  • ABAudrey A. Bolyard
    Audrey A. Bolyard
  • MBMary Ann Bonilla
    Mary Ann Bonilla
  • LBLaurence A. Boxer
    Laurence A. Boxer
  • BCBonnie Cham
    Bonnie Cham
  • CFCarol Fier
    Carol Fier
  • MFMelvin Freedman
    Melvin Freedman
  • GKGeorge Kannourakis
    George Kannourakis
  • SKSally Kinsey
    Sally Kinsey
  • BSBeate Schwinzer
    Beate Schwinzer
  • CZConnie Zeidler
    Connie Zeidler

Abstract
In patients with severe congenital neutropenia (SCN), sepsis mortality is reduced by treatment with granulocyte colony-stimulating factor (G-CSF), but myelodsyplastic syndrome and acute myeloid leukemia (MDS/AML) have been reported. We studied 374 patients with SCN and 29 patients with Shwachman-Diamond syndrome (SDS) on long-term G-CSF enrolled in the Severe Chronic Neutropenia International Registry. In SCN, sepsis mortality was stable at 0.9% per year. The hazard of MDS/AML increased significantly over time, from 2.9% per year after 6 years to 8.0% per year after 12 years on G-CSF. After 10 years, the cumulative incidence was 8% for sepsis mortality and 21% for MDS/AML. A subgroup of SCN patients (29%) received more than the median dose of G-CSF (≥ 8 μg/kg/d), but achieved less than the median absolute neutrophil count (ANC) response (ANC < 2.188 × 109/L [2188/μL] at 6-18 months). In these less-responsive patients, the cumulative incidence of adverse events was highest: after 10 years, 40% developed MDS/AML and 14% died of sepsis, compared with 11% and 4%, respectively, of more responsive patients whose ANC was above the median on doses of G-CSF below the median. Risk of MDS/AML may be similar in SDS and SCN. In less-responsive SCN patients, early hematopoietic stem cell transplantation may be a rational option.

This publication has 32 references indexed in Scilit: